Kilitch Drugs (India) (NSE:KILITCH) Interest Expense: ₹-56 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:KILITCH Kilitch Drugs (India) Ltd NSE:KILITCH
85 GF Score
Price ₹175.34
GF Value ₹226.59
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Kilitch Drugs (India) Interest Expense?

Kilitch Drugs (India) NSE:KILITCH -2.43% 85 Interest Expense is ₹-56 Mil as of Mar. 2026. GuruFocus rates NSE:KILITCH with a GF Score™ of 85/100 and a GF Value™ of ₹226.59 (Modestly Undervalued). The stock has 4 warning signs investors should review.

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Kilitch Drugs (India)'s interest expense for the three months ended in Mar. 2026 was ₹ -14 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2026 was ₹-56 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Kilitch Drugs (India)'s Operating Income for the three months ended in Mar. 2026 was ₹ 212 Mil. Kilitch Drugs (India)'s Interest Expense for the three months ended in Mar. 2026 was ₹ -14 Mil. Kilitch Drugs (India)'s Interest Coverage for the quarter that ended in Mar. 2026 was 14.65. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Kilitch Drugs (India)  (NSE:KILITCH) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Kilitch Drugs (India)'s Interest Expense for the three months ended in Mar. 2026 was ₹-14 Mil. Its Operating Income for the three months ended in Mar. 2026 was ₹212 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2026 was ₹586 Mil.

Kilitch Drugs (India)'s Interest Coverage for the quarter that ended in Mar. 2026 is calculated as

Interest Coverage=-1* Operating Income (Q: Mar. 2026 )/Interest Expense (Q: Mar. 2026 )
=-1*211.622/-14.444
=14.65

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

Kilitch Drugs (India) Interest Expense Historical Data

* Premium members only.

The historical data trend for Kilitch Drugs (India)'s Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kilitch Drugs (India) Interest Expense Chart

Kilitch Drugs (India) Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Interest Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only -11.98 -49.19 -59.29 -50.41 -55.61

Kilitch Drugs (India) Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Interest Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -16.01 -15.30 -14.40 -11.47 -14.44
NSE:KILITCH
85GF Score
Kilitch Drugs (India) Ltd NSE:KILITCH
Interest Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kilitch Drugs (India) Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹-56 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Interest Expense →
What does a Interest Expense of ₹-56 Mil mean?
Kilitch Drugs (India) (NSE:KILITCH) has a Interest Expense of ₹-56 Mil as of Mar. 2026. Interest Expense is the amount a company pays on its long-term debt. View historical data on Kilitch Drugs (India) and its competitors.
Is Kilitch Drugs (India)'s Interest Expense too high?
Kilitch Drugs (India)'s current Interest Expense is ₹-56 Mil. Overall, Kilitch Drugs (India) has a GF Score™ of 85/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Kilitch Drugs (India)'s Interest Expense compare to ZTS and UTHR?
Kilitch Drugs (India)'s Interest Expense of ₹-56 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Drug Manufacturers company?
A good Interest Expense depends on the Drug Manufacturers industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on Kilitch Drugs (India) and its competitors. Kilitch Drugs (India)'s current Interest Expense is ₹-56 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kilitch Drugs (India) stock overvalued right now?
Based on GuruFocus' analysis, Kilitch Drugs (India) (NSE:KILITCH) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹226.59, compared to a current price of ₹175.34 — trading 22.6% below its estimated fair value. The current Interest Expense is ₹-56 Mil. Kilitch Drugs (India)'s overall GF Score™ is 85/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For Kilitch Drugs (India) (NSE:KILITCH), the current Interest Expense is ₹-56 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Kilitch Drugs (India) (NSE:KILITCH) Overvalued in 2026?

Based on GuruFocus' analysis, Kilitch Drugs (India) stock appears to be undervalued. The current stock price of ₹175.34 is trading 22.6% below its estimated GF Value™ of ₹226.59. GuruFocus considers Kilitch Drugs (India) to be Modestly Undervalued.

Key valuation signals for NSE:KILITCH:

  • Interest Expense: ₹-56 Mil
  • GF Value™: ₹226.59 vs. price of ₹175.34 (22.6% below fair value)
  • GF Score™: 85/100 with 4 warning signs

No single metric tells the full story. See the NSE:KILITCH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Kilitch Drugs (India) Business Description

Other Exchanges 524500:India
Address Waman Tukaram Patil Marg, 37/39, Ujagar Industrial Estate, Deonar, Mumbai, MH, IND, 400 088
Kilitch Drugs (India) Ltd is an India-based pharmaceutical company. It is engaged in operation and management of Pharmaceutical Products. The company offers parenteral and nasal products, oral formulations, effervescent tablets, nutritional products, medical devices, and cosmetic and health products. Some of the products offered by the company are Roipar, Roivit, PH-7, C-Seal, SRO kit, 9-VIT, and HPURE. The company has one reportable segment, which is the development and operations of the Pharmaceutical business.
85GF Score

Get the complete analysis for NSE:KILITCH

Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹175.34
Price
₹226.59
GF Value